JPRN-jRCT1050230026
Recruiting
未知
Outcome of treatment for castration-resistant prostate cancer with homologous recombination repair-related gene mutations (multiinstitutional prospective observational study). - HRRCAP
Goto Takayuki0 sites400 target enrollmentMay 23, 2023
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- prostate cancer
- Sponsor
- Goto Takayuki
- Enrollment
- 400
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Patients with castration\-resistant prostate cancer who have mutations in any of the following homologous recombination repair\-related genes as a result of germline analysis (BRACAnalysis) or cancer panel testing with all of the following HRR\-related 15 genes as targets, and who have agreed to a prospective observational study
- •Homologous recombination repair gene mutations of interest: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L
- •2\) Patients who have agreed to undergo genetic analysis of their blood before starting treatment and at the time of acquisition of resistance to treatment when using PARP inhibitors or platinum drugs or immune checkpoint inhibitors during prospective observational studies
- •3\) Those who were 20 years of age or older at the time of obtaining consent
Exclusion Criteria
- •1\) Patients for whom routine follow\-up, including imaging, is not possible due to comorbidities or other reasons
- •2\) Other patients deemed unsuitable by the principal investigator or sub\-investigator to conduct the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Pharmacogenetic study in castration-resistant prostate cancer patients treated with abiraterone acetateEUCTR2012-005036-28-FRCENTRE ANTOINE LACASSAGNE330
Not yet recruiting
Not Applicable
Evaluation of the mechanisms for castration-resistance using CRPC tissues to predict the efficacy of EnzalutamideJPRN-UMIN000019277Kyoto University40
Recruiting
Phase 2
Treatment of patients with castration-resistant metastatic prostate cancer with nuclear medicine procedureCastration resistant metastatic prostate cancer.Malignant neoplasm of prostateIRCT20180113038331N1Mashhad University of Medical Sciences20
Active, not recruiting
Not Applicable
Study on the treatment of therapy-resistant enuresis with desmopressin and reboxetine; a randomised, placebo-controlled, double-blinded, cross-over studyEUCTR2008-002636-15-SEppsala University Children´s Hospital
Recruiting
Not Applicable
Metastatic hormone-sensitive and castration resistant prostate cancer registry: CAPRI 3.0NL-OMON24783Radboud University Medical Center10,000